<?xml version="1.0" encoding="UTF-8" ?>
			<?xml-stylesheet href="/rss/rss2html.xsl" type="text/xsl" media="screen"?>
			<rss version="2.0" xmlns:alacra="http://www.alacra.com" xmlns:ccbn="http://www.alacra.com/ccbn" xmlns:moodys="http://www.alacra.com/moodys" xmlns:fitch="http://www.alacra.com/fitch" xmlns:newstex="http://www.alacra.com/newstex" ><channel><title>GlaxoSmithKline plc RSS Research Feed - Subscribe Today - AlacraStore.com</title>
<description>GlaxoSmithKline plc</description>
<link>http://www.alacrastore.com/company-snapshot/GlaxoSmithKline_plc-1007127</link>
<lastBuildDate>25 Nov 2009 04:23:23 EST</lastBuildDate>
<alacra:xlsid>1007127</alacra:xlsid>
<alacra:company>GlaxoSmithKline plc</alacra:company>
<language>en</language>
<generator>AlacraStore RSS Builder 1.0</generator>
<ttl>30</ttl>
<item><link>http://www.alacrastore.com/storecontent/newstex/BW-0001-39969355</link><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">BW-0001-39969355</newstex:docid><guid isPermaLink="false">newstex/BW-0001-39969355</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><newstex:Contributor xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Contributor><newstex:CopyrightDate xmlns:newstex="http://www.alacra.com/newstex">2005</newstex:CopyrightDate><newstex:CreditLine xmlns:newstex="http://www.alacra.com/newstex">Gilead Sciences, Inc.</newstex:CreditLine><newstex:Provider xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Provider><newstex:ProviderId xmlns:newstex="http://www.alacra.com/newstex">newstex.com</newstex:ProviderId><newstex:PublicIdentifier xmlns:newstex="http://www.alacra.com/newstex">newstexBW-0001-39969355</newstex:PublicIdentifier><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publication><newstex:PublicationCode xmlns:newstex="http://www.alacra.com/newstex">0001</newstex:PublicationCode><newstex:Publisher xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publisher><newstex:PublisherCode xmlns:newstex="http://www.alacra.com/newstex">BW</newstex:PublisherCode><newstex:RevisionId xmlns:newstex="http://www.alacra.com/newstex">1</newstex:RevisionId><newstex:Source xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Source><newstex:SourceId xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:SourceId><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><pubDate>24 Nov 2009 10:21:38 EST</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18022000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002004</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002013</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002009</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002007</newstex:geo><newstex:loaddate xmlns:newstex="http://www.alacra.com/newstex">11/24/2009</newstex:loaddate><title>Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries</title><description> Nov. ##, #### (Business Wire) --  Gilead Sciences, Inc. (Nasdaq:GILD) and GlaxoSmithKline (NYSE:GSK) today announced a licensing agreement to commercialize Viread Â® (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis...</description><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GILEAD SCIENCES INC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GLAXOSMITHKLINE PLC</newstex:index_entry_company><newstex:index_entry_person xmlns:newstex="http://www.alacra.com/newstex">JOHN C MARTIN</newstex:index_entry_person><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GILD</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GSK</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/BW-0001-39782400</link><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">BW-0001-39782400</newstex:docid><guid isPermaLink="false">newstex/BW-0001-39782400</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><newstex:Contributor xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Contributor><newstex:CopyrightDate xmlns:newstex="http://www.alacra.com/newstex">2005</newstex:CopyrightDate><newstex:CreditLine xmlns:newstex="http://www.alacra.com/newstex">Anacor Pharmaceuticals</newstex:CreditLine><newstex:Provider xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Provider><newstex:ProviderId xmlns:newstex="http://www.alacra.com/newstex">newstex.com</newstex:ProviderId><newstex:PublicIdentifier xmlns:newstex="http://www.alacra.com/newstex">newstexBW-0001-39782400</newstex:PublicIdentifier><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publication><newstex:PublicationCode xmlns:newstex="http://www.alacra.com/newstex">0001</newstex:PublicationCode><newstex:Publisher xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publisher><newstex:PublisherCode xmlns:newstex="http://www.alacra.com/newstex">BW</newstex:PublisherCode><newstex:RevisionId xmlns:newstex="http://www.alacra.com/newstex">1</newstex:RevisionId><newstex:Source xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Source><newstex:SourceId xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:SourceId><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">11000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">11002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><pubDate>17 Nov 2009 08:22:36 EST</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18022000</newstex:event><newstex:loaddate xmlns:newstex="http://www.alacra.com/newstex">11/17/2009</newstex:loaddate><title>Anacor Initiates Phase I Clinical Development for AN3365 - A Novel Antibiotic for the Treatment of Gram-Negative Infections</title><description> Nov. ##, #### (Business Wire) --  Anacor Pharmaceuticals today announced that it has dosed the first patient in a Phase I clinical study for AN####, a novel boron-based, small-molecule drug candidate in development for the treatment...</description><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ANACOR PHARMACEUTICALS INC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GLAXOSMITHKLINE PLC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">ANAC</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GSK</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/PZM-0001-39748164</link><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">PZM-0001-39748164</newstex:docid><guid isPermaLink="false">newstex/PZM-0001-39748164</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><newstex:Contributor xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Contributor><newstex:CopyrightDate xmlns:newstex="http://www.alacra.com/newstex">2005</newstex:CopyrightDate><newstex:CopyrightHolder xmlns:newstex="http://www.alacra.com/newstex">Copyright (c) 2009, GlobeNewswire.</newstex:CopyrightHolder><newstex:CreditLine xmlns:newstex="http://www.alacra.com/newstex">Nabi Biopharmaceuticals; GlaxoSmithKline Biologicals SA</newstex:CreditLine><newstex:Provider xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Provider><newstex:ProviderId xmlns:newstex="http://www.alacra.com/newstex">newstex.com</newstex:ProviderId><newstex:PublicIdentifier xmlns:newstex="http://www.alacra.com/newstex">newstexPZM-0001-39748164</newstex:PublicIdentifier><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">GlobeNewswire</newstex:Publication><newstex:PublicationCode xmlns:newstex="http://www.alacra.com/newstex">0001</newstex:PublicationCode><newstex:Publisher xmlns:newstex="http://www.alacra.com/newstex">GlobeNewswire</newstex:Publisher><newstex:PublisherCode xmlns:newstex="http://www.alacra.com/newstex">PZM</newstex:PublisherCode><newstex:RevisionId xmlns:newstex="http://www.alacra.com/newstex">1</newstex:RevisionId><newstex:Source xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Source><newstex:SourceId xmlns:newstex="http://www.alacra.com/newstex">GlobeNewswire</newstex:SourceId><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">14000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">14001000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">10000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">10009000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016003</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016013</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04013000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04013008</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07015000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07015004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014019</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13001000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13001002</newstex:cat><pubDate>16 Nov 2009 07:25:15 EST</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18015000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18004000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18008000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18020000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18022000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002007</newstex:geo><newstex:loaddate xmlns:newstex="http://www.alacra.com/newstex">11/16/2009</newstex:loaddate><title>GSK and Nabi Announce Agreement for NicVAX(R), a Vaccine for Nicotine Addiction</title><description> GlobeNewswire delivered by Newstex) --  LONDON and ROCKVILLE, Md., Nov. ##, #### (GLOBE NEWSWIRE) -- GlaxoSmithKline Biologicals SA (GSK) and Nabi Biopharmaceuticals (Nabi) today announced an exclusive worldwide option and licensing...</description><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GLAXOSMITHKLINE PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">NABI BIOPHARMACEUTICALS</newstex:index_entry_company><newstex:index_entry_person xmlns:newstex="http://www.alacra.com/newstex">RAAFAT E FAHIM</newstex:index_entry_person><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GSK</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">NABI</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/BW-0001-39631579</link><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">BW-0001-39631579</newstex:docid><guid isPermaLink="false">newstex/BW-0001-39631579</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><newstex:Contributor xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Contributor><newstex:CopyrightDate xmlns:newstex="http://www.alacra.com/newstex">2005</newstex:CopyrightDate><newstex:CreditLine xmlns:newstex="http://www.alacra.com/newstex">Parker Waichman Alonso LLP</newstex:CreditLine><newstex:Provider xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Provider><newstex:ProviderId xmlns:newstex="http://www.alacra.com/newstex">newstex.com</newstex:ProviderId><newstex:PublicIdentifier xmlns:newstex="http://www.alacra.com/newstex">newstexBW-0001-39631579</newstex:PublicIdentifier><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publication><newstex:PublicationCode xmlns:newstex="http://www.alacra.com/newstex">0001</newstex:PublicationCode><newstex:Publisher xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publisher><newstex:PublisherCode xmlns:newstex="http://www.alacra.com/newstex">BW</newstex:PublisherCode><newstex:RevisionId xmlns:newstex="http://www.alacra.com/newstex">1</newstex:RevisionId><newstex:Source xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Source><newstex:SourceId xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:SourceId><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04012000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04012004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014019</newstex:cat><pubDate>11 Nov 2009 01:18:31 EST</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18014000</newstex:event><newstex:loaddate xmlns:newstex="http://www.alacra.com/newstex">11/11/2009</newstex:loaddate><title>Parker Waichman Alonso LLP Files Suit Against the Manufacturers of Super PoliGrip(R) and Fixodent(R) on Behalf of a Woman Suffering From Denture Cream Zinc Poisoning</title><description> Nov. ##, #### (Business Wire) --  Parker Waichman Alonso LLP announces that they have filed a lawsuit against GlaxoSmithKline and Procter &amp; Gamble on behalf of an Nebraska woman who was diagnosed with neuropathy attributed to the use...</description><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GLAXOSMITHKLINE PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PROCTER &amp; GAMBLE CO</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GSK</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PG</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/research/moodys-global-credit-research-GlaxoSmithKline_plc-PBC_121080</link><moodys:docid xmlns:moodys="http://www.alacra.com/moodys">PBC_121080</moodys:docid><guid isPermaLink="false">moodys/PBC_121080</guid><moodys:index_mode xmlns:moodys="http://www.alacra.com/moodys">pdf</moodys:index_mode><pubDate>09 Nov 2009 12:17:00 EST</pubDate><moodys:format xmlns:moodys="http://www.alacra.com/moodys">pdf</moodys:format><moodys:issuer xmlns:moodys="http://www.alacra.com/moodys">GlaxoSmithKline plc</moodys:issuer><moodys:issuer_list xmlns:moodys="http://www.alacra.com/moodys">GlaxoSmithKline plc</moodys:issuer_list><moodys:moodys_org_id xmlns:moodys="http://www.alacra.com/moodys">600057581</moodys:moodys_org_id><moodys:org_id xmlns:moodys="http://www.alacra.com/moodys">600057581</moodys:org_id><moodys:price xmlns:moodys="http://www.alacra.com/moodys">300.0000</moodys:price><moodys:printdate xmlns:moodys="http://www.alacra.com/moodys">09 Nov 2009</moodys:printdate><moodys:report_class xmlns:moodys="http://www.alacra.com/moodys">Analysis</moodys:report_class><moodys:report_type xmlns:moodys="http://www.alacra.com/moodys">Analysis</moodys:report_type><moodys:sector xmlns:moodys="http://www.alacra.com/moodys">C</moodys:sector><title>GlaxoSmithKline plc</title><description>...Headquartered in the UK, GlaxoSmithKline plc (GSK, rated A#/negative) was created from the merger of Glaxo Wellcome plc and SmithKline Beecham plc in December ####. Taking account of the recent consolidation wave (i.e. Pfizer/Wyeth and Merck/Schering-Plough), GSK ranks number three worldwide for prescription drugs, with a market share of approximately #%. GSK operates in diversified therapeutic areas (see Figure #) and it also manufactures and markets consumer health-related products: over-the-counter (OTC) medicines, oral healthcare and nutritional healthcare....

</description><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">100015</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">100015</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">100050</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">100050</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">100075</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">100075</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">100100</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">100100</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">100130</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">100130</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">100140</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">100140</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">1805</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">1805</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">21800</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">21800</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">228900</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">228900</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">2784</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">2784</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">363400</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">363400</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">448400</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">448400</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">525600</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">525600</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">578700</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">578700</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">600008628</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">600008628</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">600010089</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">600010089</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">600010708</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">600010708</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">600020139</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">600020139</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">600035689</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">600035689</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">600041100</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">600041100</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">600057581</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">600057581</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">600061925</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">600061925</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">683000</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">683000</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">710700</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">710700</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">739250</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">739250</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">806800188</moodys:index_entry_child_id><moodys:index_entry_child_id xmlns:moodys="http://www.alacra.com/moodys">806800188</moodys:index_entry_child_id><moodys:index_entry_country xmlns:moodys="http://www.alacra.com/moodys">UNITED KINGDOM</moodys:index_entry_country><moodys:index_entry_country xmlns:moodys="http://www.alacra.com/moodys">UNITED KINGDOM</moodys:index_entry_country><moodys:index_entry_industry xmlns:moodys="http://www.alacra.com/moodys">INDUSTRIAL</moodys:index_entry_industry><moodys:index_entry_industry xmlns:moodys="http://www.alacra.com/moodys">INDUSTRIAL</moodys:index_entry_industry><moodys:index_entry_ultparent_id xmlns:moodys="http://www.alacra.com/moodys">600057581</moodys:index_entry_ultparent_id><moodys:index_entry_ultparent_id xmlns:moodys="http://www.alacra.com/moodys">600057581</moodys:index_entry_ultparent_id><category>Credit &amp; Investment Research</category><alacra:ip>Moody's Global Credit Research</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/MCOM-0004-39460563</link><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">MCOM-0004-39460563</newstex:docid><guid isPermaLink="false">newstex/MCOM-0004-39460563</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><newstex:Contributor xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Contributor><newstex:CopyrightDate xmlns:newstex="http://www.alacra.com/newstex">2005</newstex:CopyrightDate><newstex:CopyrightHolder xmlns:newstex="http://www.alacra.com/newstex">Copyright (c) M2 Communications Ltd.</newstex:CopyrightHolder><newstex:Provider xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Provider><newstex:ProviderId xmlns:newstex="http://www.alacra.com/newstex">newstex.com</newstex:ProviderId><newstex:PublicIdentifier xmlns:newstex="http://www.alacra.com/newstex">newstexMCOM-0004-39460563</newstex:PublicIdentifier><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">M2 EquityBites</newstex:Publication><newstex:PublicationCode xmlns:newstex="http://www.alacra.com/newstex">0004</newstex:PublicationCode><newstex:Publisher xmlns:newstex="http://www.alacra.com/newstex">M2 Communications Ltd.</newstex:Publisher><newstex:PublisherCode xmlns:newstex="http://www.alacra.com/newstex">MCOM</newstex:PublisherCode><newstex:RevisionId xmlns:newstex="http://www.alacra.com/newstex">1</newstex:RevisionId><newstex:Source xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Source><newstex:SourceId xmlns:newstex="http://www.alacra.com/newstex">M2</newstex:SourceId><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016013</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04006000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04006005</newstex:cat><pubDate>05 Nov 2009 11:18:11 EST</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18015000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18022000</newstex:event><newstex:loaddate xmlns:newstex="http://www.alacra.com/newstex">11/5/2009</newstex:loaddate><title>GlaxoSmithKline and Pfizer launch HIV joint venture</title><description> Nov. #, #### (M# Communications Ltd. delivered by Newstex) -- Healthcare company GlaxoSmithKline plc (GSK) (LSE:GSK) confirmed on Tuesday the launch of a new specialist HIV company in partnership with pharmaceutical group Pfizer Inc...</description><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GLAXOSMITHKLINE PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PFIZER INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GSK</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PFE</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/BW-0001-39422386</link><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">BW-0001-39422386</newstex:docid><guid isPermaLink="false">newstex/BW-0001-39422386</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><newstex:Contributor xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Contributor><newstex:CopyrightDate xmlns:newstex="http://www.alacra.com/newstex">2005</newstex:CopyrightDate><newstex:CreditLine xmlns:newstex="http://www.alacra.com/newstex">Synta Pharmaceuticals Corp.</newstex:CreditLine><newstex:Provider xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Provider><newstex:ProviderId xmlns:newstex="http://www.alacra.com/newstex">newstex.com</newstex:ProviderId><newstex:PublicIdentifier xmlns:newstex="http://www.alacra.com/newstex">newstexBW-0001-39422386</newstex:PublicIdentifier><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publication><newstex:PublicationCode xmlns:newstex="http://www.alacra.com/newstex">0001</newstex:PublicationCode><newstex:Publisher xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publisher><newstex:PublisherCode xmlns:newstex="http://www.alacra.com/newstex">BW</newstex:PublisherCode><newstex:RevisionId xmlns:newstex="http://www.alacra.com/newstex">1</newstex:RevisionId><newstex:Source xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Source><newstex:SourceId xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:SourceId><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016018</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016003</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016013</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><pubDate>04 Nov 2009 08:26:54 EST</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18004000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18022000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18015000</newstex:event><newstex:loaddate xmlns:newstex="http://www.alacra.com/newstex">11/4/2009</newstex:loaddate><title>Synta Pharmaceuticals Reports Third Quarter 2009 Financial Results</title><description> Nov. #, #### (Business Wire) --  Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported...</description><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GLAXOSMITHKLINE PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">SYNTA PHARMACEUTICALS CORP.</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GSK</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">SNTA</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/BW-0001-39370312</link><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">BW-0001-39370312</newstex:docid><guid isPermaLink="false">newstex/BW-0001-39370312</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><newstex:Contributor xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Contributor><newstex:CopyrightDate xmlns:newstex="http://www.alacra.com/newstex">2005</newstex:CopyrightDate><newstex:CreditLine xmlns:newstex="http://www.alacra.com/newstex">Parker Waichman Alonso LLP</newstex:CreditLine><newstex:Provider xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Provider><newstex:ProviderId xmlns:newstex="http://www.alacra.com/newstex">newstex.com</newstex:ProviderId><newstex:PublicIdentifier xmlns:newstex="http://www.alacra.com/newstex">newstexBW-0001-39370312</newstex:PublicIdentifier><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publication><newstex:PublicationCode xmlns:newstex="http://www.alacra.com/newstex">0001</newstex:PublicationCode><newstex:Publisher xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publisher><newstex:PublisherCode xmlns:newstex="http://www.alacra.com/newstex">BW</newstex:PublisherCode><newstex:RevisionId xmlns:newstex="http://www.alacra.com/newstex">1</newstex:RevisionId><newstex:Source xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Source><newstex:SourceId xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:SourceId><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04012000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04012004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014019</newstex:cat><pubDate>02 Nov 2009 04:27:45 EST</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18014000</newstex:event><newstex:loaddate xmlns:newstex="http://www.alacra.com/newstex">11/2/2009</newstex:loaddate><title>Parker Waichman Alonso LLP Files Suit Against the Manufacturers of Super PoliGrip(R) and Fixodent(R) on Behalf of a Victim of Denture Cream Zinc Poisoning</title><description> Nov. #, #### (Business Wire) --  Parker Waichman Alonso LLP announces that they have filed a lawsuit against GlaxoSmithKline and Proctor &amp; Gamble on behalf of an Iowa woman who was diagnosed with neuropathy attributed to the use of...</description><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GLAXOSMITHKLINE PLC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GSK</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/research/fitch-ratings-GlaxoSmithKline_PLC-478646_report_frame</link><fitch:docid xmlns:fitch="http://www.alacra.com/fitch">478646_report_frame</fitch:docid><guid isPermaLink="false">fitch/478646_report_frame</guid><fitch:index_mode xmlns:fitch="http://www.alacra.com/fitch">pdf</fitch:index_mode><fitch:company xmlns:fitch="http://www.alacra.com/fitch">GlaxoSmithKline plc</fitch:company><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80457972</fitch:companyid><pubDate>31 Oct 2009 10:21:00 EST</pubDate><fitch:industry xmlns:fitch="http://www.alacra.com/fitch">01031700</fitch:industry><fitch:price xmlns:fitch="http://www.alacra.com/fitch">165</fitch:price><fitch:report xmlns:fitch="http://www.alacra.com/fitch">Credit Update</fitch:report><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">GSK</fitch:ticker><title>GlaxoSmithKline PLC</title><description>Fitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.</description><fitch:index_entry_country_code xmlns:fitch="http://www.alacra.com/fitch">ARG</fitch:index_entry_country_code><fitch:index_entry_country_code xmlns:fitch="http://www.alacra.com/fitch">DEU</fitch:index_entry_country_code><fitch:index_entry_country_code xmlns:fitch="http://www.alacra.com/fitch">ESP</fitch:index_entry_country_code><fitch:index_entry_country_code xmlns:fitch="http://www.alacra.com/fitch">GBR</fitch:index_entry_country_code><fitch:index_entry_country_code xmlns:fitch="http://www.alacra.com/fitch">IND</fitch:index_entry_country_code><fitch:index_entry_country_code xmlns:fitch="http://www.alacra.com/fitch">MEX</fitch:index_entry_country_code><fitch:index_entry_country_code xmlns:fitch="http://www.alacra.com/fitch">RUS</fitch:index_entry_country_code><fitch:index_entry_country_code xmlns:fitch="http://www.alacra.com/fitch">USA</fitch:index_entry_country_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">01010000</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">01010100</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">01020000</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">01030000</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">01031000</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">01031700</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">02020000</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">03000000</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">03010000</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">03010800</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">03020000</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">03030000</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">04000000</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">04010000</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">04020000</fitch:index_entry_mkt_sector_code><category>Credit &amp; Investment Research</category><alacra:ip>Fitch Research</alacra:ip></item><item><link>http://www.alacrastore.com/research/fitch-ratings-Fitch_European_Pharma_Faces_Declining_Profitability_on_Diversification_Pressures-524736_pr_frame</link><fitch:docid xmlns:fitch="http://www.alacra.com/fitch">524736_pr_frame</fitch:docid><guid isPermaLink="false">fitch/524736_pr_frame</guid><fitch:index_mode xmlns:fitch="http://www.alacra.com/fitch">html</fitch:index_mode><fitch:company xmlns:fitch="http://www.alacra.com/fitch">AstraZeneca plc</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Bayer AG</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Glaxosmithkline Finance Plc</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">GlaxoSmithKline plc</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Novartis AG</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Roche Holding Ltd.</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Sanofi-Aventis S.A.</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Smithkline Beecham Corporation</fitch:company><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80362434</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80457972</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80457976</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80457979</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">81108707</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">81108717</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">82588683</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">85884073</fitch:companyid><pubDate>29 Oct 2009 10:17:00 EST</pubDate><fitch:industry xmlns:fitch="http://www.alacra.com/fitch">01031700</fitch:industry><fitch:price xmlns:fitch="http://www.alacra.com/fitch">85</fitch:price><fitch:report xmlns:fitch="http://www.alacra.com/fitch">Press Release</fitch:report><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">AZN</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">BAYN</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">GSK</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">NOVN</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">RO</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">SAN</fitch:ticker><title>Fitch: European Pharma Faces Declining Profitability on Diversification Pressures</title><description>Fitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.</description><fitch:index_entry_country_code xmlns:fitch="http://www.alacra.com/fitch">ARG</fitch:index_entry_country_code><fitch:index_entry_country_code xmlns:fitch="http://www.alacra.com/fitch">CHE</fitch:index_entry_country_code><fitch:index_entry_country_code xmlns:fitch="http://www.alacra.com/fitch">DEU</fitch:index_entry_country_code><fitch:index_entry_country_code xmlns:fitch="http://www.alacra.com/fitch">ESP</fitch:index_entry_country_code><fitch:index_entry_country_code xmlns:fitch="http://www.alacra.com/fitch">FRA</fitch:index_entry_country_code><fitch:index_entry_country_code xmlns:fitch="http://www.alacra.com/fitch">GBR</fitch:index_entry_country_code><fitch:index_entry_country_code xmlns:fitch="http://www.alacra.com/fitch">IND</fitch:index_entry_country_code><fitch:index_entry_country_code xmlns:fitch="http://www.alacra.com/fitch">MEX</fitch:index_entry_country_code><fitch:index_entry_country_code xmlns:fitch="http://www.alacra.com/fitch">RUS</fitch:index_entry_country_code><fitch:index_entry_country_code xmlns:fitch="http://www.alacra.com/fitch">USA</fitch:index_entry_country_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">01010000</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">01010100</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">01020000</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">01030000</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">01031000</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">01031700</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">02020000</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">03000000</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">03010000</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">03010800</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">03020000</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">03030000</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">04000000</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">04010000</fitch:index_entry_mkt_sector_code><fitch:index_entry_mkt_sector_code xmlns:fitch="http://www.alacra.com/fitch">04020000</fitch:index_entry_mkt_sector_code><category>Credit &amp; Investment Research</category><alacra:ip>Fitch Research</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T2039548</link><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T2039548</ccbn:docid><guid isPermaLink="false">ccbn/T2039548</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><pubDate>28 Oct 2009 02:08:00 EST</pubDate><ccbn:eventid xmlns:ccbn="http://www.alacra.com/ccbn">2039548</ccbn:eventid><ccbn:headline xmlns:ccbn="http://www.alacra.com/ccbn">Final Transcript of GSK earnings conference call or presentation, 28-Oct-09 1:30pm UKT</ccbn:headline><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">GlaxoSmithKline</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">GlaxoSmithKline Q3 2009 Earnings Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">GSK</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">1:30pm UKT</ccbn:time><title>GlaxoSmithKline Q3 2009 Earnings Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><description>...Andrew Baum Morgan Stanley - Analyst Gbola Amusa UBS - Analyst Tim Anderson Sanford C. Bernstein &amp; Company, Inc. - Analyst Alexandra Hauber JPMorgan - Analyst Graham Parry BAS-ML - Analyst Kevin Wilson Citigroup - Analyst...

</description><category>Credit &amp; Investment Research</category><alacra:ip>Thomson StreetEvents</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/B2039548</link><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">B2039548</ccbn:docid><guid isPermaLink="false">ccbn/B2039548</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><pubDate>28 Oct 2009 02:08:00 EST</pubDate><ccbn:eventid xmlns:ccbn="http://www.alacra.com/ccbn">2039548</ccbn:eventid><ccbn:headline xmlns:ccbn="http://www.alacra.com/ccbn">Edited Brief of GSK earnings conference call or presentation, 28-Oct-09 1:30pm UKT</ccbn:headline><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">GlaxoSmithKline</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Edited</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">GlaxoSmithKline Q3 2009 Earnings Conference Call Summary</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">GSK</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">1:30pm UKT</ccbn:time><title>GlaxoSmithKline Q3 2009 Earnings Conference Call Summary</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Brief</ccbn:type><description>...Andrew Baum Morgan Stanley - Analyst Gbola Amusa UBS - Analyst Tim Anderson Sanford C. Bernstein &amp; Company, Inc. - Analyst Alexandra Hauber JPMorgan - Analyst Graham Parry BAS-ML - Analyst Kevin Wilson Citigroup - Analyst...

</description><category>Credit &amp; Investment Research</category><alacra:ip>Thomson StreetEvents</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/BW-0001-39198110</link><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">BW-0001-39198110</newstex:docid><guid isPermaLink="false">newstex/BW-0001-39198110</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><newstex:Contributor xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Contributor><newstex:CopyrightDate xmlns:newstex="http://www.alacra.com/newstex">2005</newstex:CopyrightDate><newstex:CreditLine xmlns:newstex="http://www.alacra.com/newstex">Parker Waichman Alonso LLP</newstex:CreditLine><newstex:Provider xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Provider><newstex:ProviderId xmlns:newstex="http://www.alacra.com/newstex">newstex.com</newstex:ProviderId><newstex:PublicIdentifier xmlns:newstex="http://www.alacra.com/newstex">newstexBW-0001-39198110</newstex:PublicIdentifier><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publication><newstex:PublicationCode xmlns:newstex="http://www.alacra.com/newstex">0001</newstex:PublicationCode><newstex:Publisher xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publisher><newstex:PublisherCode xmlns:newstex="http://www.alacra.com/newstex">BW</newstex:PublisherCode><newstex:RevisionId xmlns:newstex="http://www.alacra.com/newstex">1</newstex:RevisionId><newstex:Source xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Source><newstex:SourceId xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:SourceId><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04012000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04012004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04005009</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014019</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><pubDate>27 Oct 2009 05:27:49 EST</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18014000</newstex:event><newstex:loaddate xmlns:newstex="http://www.alacra.com/newstex">10/27/2009</newstex:loaddate><title>Parker Waichman Alonso LLP Continues to Fight for Those Sickened by Zinc-Containing Denture Adhesive Creams and Files Suit Against GlaxoSmithKline on Behalf of a Super PoliGrip(R) User Diagnosed with Neuropathy</title><description> Oct. ##, #### (Business Wire) --  Parker Waichman Alonso LLP announces that they have filed a lawsuit against GlaxoSmithKline and its subsidiaries on behalf of a South Carolina man who was diagnosed with neuropathy attributed to the...</description><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GLAXOSMITHKLINE PLC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GSK</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/BW-0001-38905498</link><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">BW-0001-38905498</newstex:docid><guid isPermaLink="false">newstex/BW-0001-38905498</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><newstex:Contributor xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Contributor><newstex:CopyrightDate xmlns:newstex="http://www.alacra.com/newstex">2005</newstex:CopyrightDate><newstex:CreditLine xmlns:newstex="http://www.alacra.com/newstex">Parker Waichman Alonso LLP</newstex:CreditLine><newstex:Provider xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Provider><newstex:ProviderId xmlns:newstex="http://www.alacra.com/newstex">newstex.com</newstex:ProviderId><newstex:PublicIdentifier xmlns:newstex="http://www.alacra.com/newstex">newstexBW-0001-38905498</newstex:PublicIdentifier><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publication><newstex:PublicationCode xmlns:newstex="http://www.alacra.com/newstex">0001</newstex:PublicationCode><newstex:Publisher xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publisher><newstex:PublisherCode xmlns:newstex="http://www.alacra.com/newstex">BW</newstex:PublisherCode><newstex:RevisionId xmlns:newstex="http://www.alacra.com/newstex">1</newstex:RevisionId><newstex:Source xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Source><newstex:SourceId xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:SourceId><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04012000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04012004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04005009</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014019</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><pubDate>16 Oct 2009 03:19:14 EST</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18014000</newstex:event><newstex:loaddate xmlns:newstex="http://www.alacra.com/newstex">10/16/2009</newstex:loaddate><title>Parker Waichman Alonso LLP Files Lawsuit Against GlaxoSmithKline on Behalf of Super PoliGrip(R) User Suffering from Denture Cream Zinc Poisoning</title><description> Oct. ##, #### (Business Wire) --  Parker Waichman Alonso LLP announces that they have filed a lawsuit against GlaxoSmithKline and its subsidiaries on behalf of a Texas man who was diagnosed with neuropathy attributed to his use of Super...</description><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GLAXOSMITHKLINE PLC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GSK</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/BW-0001-38798293</link><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">BW-0001-38798293</newstex:docid><guid isPermaLink="false">newstex/BW-0001-38798293</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><newstex:Contributor xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Contributor><newstex:CopyrightDate xmlns:newstex="http://www.alacra.com/newstex">2005</newstex:CopyrightDate><newstex:CreditLine xmlns:newstex="http://www.alacra.com/newstex">POZEN Inc.</newstex:CreditLine><newstex:Provider xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Provider><newstex:ProviderId xmlns:newstex="http://www.alacra.com/newstex">newstex.com</newstex:ProviderId><newstex:PublicIdentifier xmlns:newstex="http://www.alacra.com/newstex">newstexBW-0001-38798293</newstex:PublicIdentifier><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publication><newstex:PublicationCode xmlns:newstex="http://www.alacra.com/newstex">0001</newstex:PublicationCode><newstex:Publisher xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publisher><newstex:PublisherCode xmlns:newstex="http://www.alacra.com/newstex">BW</newstex:PublisherCode><newstex:RevisionId xmlns:newstex="http://www.alacra.com/newstex">1</newstex:RevisionId><newstex:Source xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Source><newstex:SourceId xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:SourceId><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016018</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016048</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><pubDate>14 Oct 2009 08:26:07 EST</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18004000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18008000</newstex:event><newstex:loaddate xmlns:newstex="http://www.alacra.com/newstex">10/14/2009</newstex:loaddate><title>POZEN Announces October 28, 2009 Webcast of Third Quarter 2009 Results</title><description> Oct. ##, #### (Business Wire) -- POZEN Inc. (NASDAQ: POZN) , announced today that it will release third quarter #### results on October ##, ####, before the market opens. The announcement will be followed by a live webcast at ##:##...</description><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GLAXOSMITHKLINE PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">POZEN INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GSK</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">POZN</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/BW-0001-38656988</link><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">BW-0001-38656988</newstex:docid><guid isPermaLink="false">newstex/BW-0001-38656988</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><newstex:Contributor xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Contributor><newstex:CopyrightDate xmlns:newstex="http://www.alacra.com/newstex">2005</newstex:CopyrightDate><newstex:CreditLine xmlns:newstex="http://www.alacra.com/newstex">Biotechnology Industry Organization (BIO)</newstex:CreditLine><newstex:Provider xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Provider><newstex:ProviderId xmlns:newstex="http://www.alacra.com/newstex">newstex.com</newstex:ProviderId><newstex:PublicIdentifier xmlns:newstex="http://www.alacra.com/newstex">newstexBW-0001-38656988</newstex:PublicIdentifier><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publication><newstex:PublicationCode xmlns:newstex="http://www.alacra.com/newstex">0001</newstex:PublicationCode><newstex:Publisher xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publisher><newstex:PublisherCode xmlns:newstex="http://www.alacra.com/newstex">BW</newstex:PublisherCode><newstex:RevisionId xmlns:newstex="http://www.alacra.com/newstex">1</newstex:RevisionId><newstex:Source xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Source><newstex:SourceId xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:SourceId><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13002005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><pubDate>08 Oct 2009 06:19:31 EST</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18018000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002007</newstex:geo><newstex:loaddate xmlns:newstex="http://www.alacra.com/newstex">10/8/2009</newstex:loaddate><title>BIO Commends PTO Director for Withdrawal of Harmful Rules</title><description> Oct. #, #### (Business Wire) --  Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood issued the following statement today on the decision by David J. Kappos, Under Secretary of Commerce for Intellectual Property...</description><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GLAXOSMITHKLINE PLC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GSK</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/BW-0001-38644096</link><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">BW-0001-38644096</newstex:docid><guid isPermaLink="false">newstex/BW-0001-38644096</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><newstex:Contributor xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Contributor><newstex:CopyrightDate xmlns:newstex="http://www.alacra.com/newstex">2005</newstex:CopyrightDate><newstex:CreditLine xmlns:newstex="http://www.alacra.com/newstex">Parker Waichman Alonso LLP</newstex:CreditLine><newstex:Provider xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Provider><newstex:ProviderId xmlns:newstex="http://www.alacra.com/newstex">newstex.com</newstex:ProviderId><newstex:PublicIdentifier xmlns:newstex="http://www.alacra.com/newstex">newstexBW-0001-38644096</newstex:PublicIdentifier><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publication><newstex:PublicationCode xmlns:newstex="http://www.alacra.com/newstex">0001</newstex:PublicationCode><newstex:Publisher xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publisher><newstex:PublisherCode xmlns:newstex="http://www.alacra.com/newstex">BW</newstex:PublisherCode><newstex:RevisionId xmlns:newstex="http://www.alacra.com/newstex">1</newstex:RevisionId><newstex:Source xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Source><newstex:SourceId xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:SourceId><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04012000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04012004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04005009</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014019</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><pubDate>08 Oct 2009 11:25:09 EST</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18014000</newstex:event><newstex:loaddate xmlns:newstex="http://www.alacra.com/newstex">10/8/2009</newstex:loaddate><title>Parker Waichman Alonso LLP Continues to Fight for Those Sickened by Zinc-Containing Denture Adhesive Creams and Files Suit Against GlaxoSmithKline on Behalf of a Super PoliGrip(R) User Diagnosed with Neuropathy</title><description> Oct. #, #### (Business Wire) --  Parker Waichman Alonso LLP announces that they have filed a lawsuit against GlaxoSmithKline and its subsidiaries on behalf of a North Carolina woman who was diagnosed with neuropathy attributed to the...</description><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GLAXOSMITHKLINE PLC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GSK</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/MW-0001-38638168</link><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">MW-0001-38638168</newstex:docid><guid isPermaLink="false">newstex/MW-0001-38638168</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><newstex:Contributor xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Contributor><newstex:CopyrightDate xmlns:newstex="http://www.alacra.com/newstex">2005</newstex:CopyrightDate><newstex:CopyrightHolder xmlns:newstex="http://www.alacra.com/newstex">Copyright (c) 2009, Marketwire. All rights reserved. All the news releases provided by Market Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited.</newstex:CopyrightHolder><newstex:CreditLine xmlns:newstex="http://www.alacra.com/newstex">RetroVirox Inc.</newstex:CreditLine><newstex:DateLine xmlns:newstex="http://www.alacra.com/newstex">SAN DIEGO, CA</newstex:DateLine><newstex:Provider xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Provider><newstex:ProviderId xmlns:newstex="http://www.alacra.com/newstex">newstex.com</newstex:ProviderId><newstex:PublicIdentifier xmlns:newstex="http://www.alacra.com/newstex">newstexMW-0001-38638168</newstex:PublicIdentifier><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Marketwire</newstex:Publication><newstex:PublicationCode xmlns:newstex="http://www.alacra.com/newstex">0001</newstex:PublicationCode><newstex:Publisher xmlns:newstex="http://www.alacra.com/newstex">Marketwire</newstex:Publisher><newstex:PublisherCode xmlns:newstex="http://www.alacra.com/newstex">MW</newstex:PublisherCode><newstex:RevisionId xmlns:newstex="http://www.alacra.com/newstex">1</newstex:RevisionId><newstex:Source xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Source><newstex:SourceId xmlns:newstex="http://www.alacra.com/newstex">Marketwire</newstex:SourceId><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">09000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">09015000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016008</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><pubDate>08 Oct 2009 08:22:49 EST</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18007000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19001000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19001005</newstex:geo><newstex:loaddate xmlns:newstex="http://www.alacra.com/newstex">10/8/2009</newstex:loaddate><title>RetroVirox Announces Appointment of Dr. Ronald C. Griffith as Vice President of Research and Development</title><description> SAN DIEGO, CA, Oct. #, #### (Marketwire delivered by Newstex) -- SAN DIEGO, CA -- (Marketwire) -- ##/##/## --  RetroVirox, Inc., a biotechnology company focused on developing novel antivirals, announced today the appointment of Ronald...</description><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ASTRAZENECA PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GLAXOSMITHKLINE PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">NOVARTIS AG</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">AZN</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GSK</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">NVS</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/BW-0001-38631186</link><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">BW-0001-38631186</newstex:docid><guid isPermaLink="false">newstex/BW-0001-38631186</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><newstex:Contributor xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Contributor><newstex:CopyrightDate xmlns:newstex="http://www.alacra.com/newstex">2005</newstex:CopyrightDate><newstex:CreditLine xmlns:newstex="http://www.alacra.com/newstex">APP Pharmaceuticals, Inc.</newstex:CreditLine><newstex:Provider xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Provider><newstex:ProviderId xmlns:newstex="http://www.alacra.com/newstex">newstex.com</newstex:ProviderId><newstex:PublicIdentifier xmlns:newstex="http://www.alacra.com/newstex">newstexBW-0001-38631186</newstex:PublicIdentifier><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publication><newstex:PublicationCode xmlns:newstex="http://www.alacra.com/newstex">0001</newstex:PublicationCode><newstex:Publisher xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publisher><newstex:PublisherCode xmlns:newstex="http://www.alacra.com/newstex">BW</newstex:PublisherCode><newstex:RevisionId xmlns:newstex="http://www.alacra.com/newstex">1</newstex:RevisionId><newstex:Source xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Source><newstex:SourceId xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:SourceId><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016001</newstex:cat><pubDate>08 Oct 2009 02:22:39 EST</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18020000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18016000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19001000</newstex:geo><newstex:loaddate xmlns:newstex="http://www.alacra.com/newstex">10/8/2009</newstex:loaddate><title>APP Pharmaceuticals Receives Approval for Sumatriptan Succinate Injection, USP</title><description> Oct. #, #### (Business Wire) --  APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration...</description><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">FRESENIUS KABI PHARMACEUTICALS HOLDING INC.</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GLAXOSMITHKLINE PLC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">APCVZ</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GSK</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/BW-0001-38613636</link><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">BW-0001-38613636</newstex:docid><guid isPermaLink="false">newstex/BW-0001-38613636</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><newstex:Contributor xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Contributor><newstex:CopyrightDate xmlns:newstex="http://www.alacra.com/newstex">2005</newstex:CopyrightDate><newstex:CreditLine xmlns:newstex="http://www.alacra.com/newstex">Parker Waichman Alonso LLP</newstex:CreditLine><newstex:Provider xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Provider><newstex:ProviderId xmlns:newstex="http://www.alacra.com/newstex">newstex.com</newstex:ProviderId><newstex:PublicIdentifier xmlns:newstex="http://www.alacra.com/newstex">newstexBW-0001-38613636</newstex:PublicIdentifier><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publication><newstex:PublicationCode xmlns:newstex="http://www.alacra.com/newstex">0001</newstex:PublicationCode><newstex:Publisher xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publisher><newstex:PublisherCode xmlns:newstex="http://www.alacra.com/newstex">BW</newstex:PublisherCode><newstex:RevisionId xmlns:newstex="http://www.alacra.com/newstex">1</newstex:RevisionId><newstex:Source xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Source><newstex:SourceId xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:SourceId><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04012000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04012004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04005009</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014019</newstex:cat><pubDate>07 Oct 2009 11:26:18 EST</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18014000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002004</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19001010</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002007</newstex:geo><newstex:loaddate xmlns:newstex="http://www.alacra.com/newstex">10/7/2009</newstex:loaddate><title>Parker Waichman Alonso LLP Files Yet Another Lawsuit Against GlaxoSmithKline on Behalf of an Individual Stricken with Neuropathy Attributed to Zinc in Super PoliGrip(R)</title><description> Oct. #, #### (Business Wire) --  Parker Waichman Alonso LLP announces that they have filed a lawsuit against GlaxoSmithKline and its subsidiaries on behalf of a Georgia woman who was diagnosed with neuropathy attributed to the use of...</description><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GLAXOSMITHKLINE PLC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GSK</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item></channel></rss>